233 related articles for article (PubMed ID: 32111748)
1. Targeting BCL-2 as a Therapeutic Strategy for Primary
Massimino M; Tirrò E; Stella S; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Romeo MA; DI Raimondo F; Manzella L
In Vivo; 2020; 34(2):511-516. PubMed ID: 32111748
[TBL] [Abstract][Full Text] [Related]
2. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
3. High frequency of BTG1 deletions in patients with BCR-ABL1-positive acute leukemia.
Xie J; Wang Q; Wang Q; Yao H; Wen L; Ma L; Wu D; Chen S
Cancer Genet; 2014 May; 207(5):226-30. PubMed ID: 24998463
[TBL] [Abstract][Full Text] [Related]
4. SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
Gu S; Sayad A; Chan G; Yang W; Lu Z; Virtanen C; Van Etten RA; Neel BG
Leukemia; 2018 Jan; 32(1):203-213. PubMed ID: 28804122
[TBL] [Abstract][Full Text] [Related]
5. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
[TBL] [Abstract][Full Text] [Related]
6. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
[TBL] [Abstract][Full Text] [Related]
7. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
8. Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.
Gu S; Chan WW; Mohi G; Rosenbaum J; Sayad A; Lu Z; Virtanen C; Li S; Neel BG; Van Etten RA
Blood; 2016 Apr; 127(14):1803-13. PubMed ID: 26773044
[TBL] [Abstract][Full Text] [Related]
9. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
[TBL] [Abstract][Full Text] [Related]
10. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.
Geng H; Brennan S; Milne TA; Chen WY; Li Y; Hurtz C; Kweon SM; Zickl L; Shojaee S; Neuberg D; Huang C; Biswas D; Xin Y; Racevskis J; Ketterling RP; Luger SM; Lazarus H; Tallman MS; Rowe JM; Litzow MR; Guzman ML; Allis CD; Roeder RG; Müschen M; Paietta E; Elemento O; Melnick AM
Cancer Discov; 2012 Nov; 2(11):1004-23. PubMed ID: 23107779
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous occurrence of ETV6-RUNX1 and BCR-ABL1 (e1a2) transcripts in a child with B-cell acute lymphoblastic leukemia.
Balatzenko G; Guenova M; Kalinova I; Belcheva M; Hristozova H; Kaleva V
Cancer Genet; 2013 Mar; 206(3):97-101. PubMed ID: 23491079
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.
Xue M; Wang Q; Huo L; Wen L; Yang X; Wu Q; Pan J; Cen J; Ruan C; Wu D; Chen S
Leuk Lymphoma; 2019 Dec; 60(12):3051-3057. PubMed ID: 31258010
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations.
van Outersterp I; Boer JM; van de Ven C; Reichert CEJ; Boeree A; Kruisinga B; de Groot-Kruseman HA; Escherich G; Sijs-Szabo A; Rijneveld AW; den Boer ML
Blood Adv; 2024 Apr; 8(8):1835-1845. PubMed ID: 38386975
[TBL] [Abstract][Full Text] [Related]
14. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
15. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract][Full Text] [Related]
16. In vivo RNAi screening identifies
Fiedler ERC; Bhutkar A; Lawler E; Besada R; Hemann MT
Blood Adv; 2018 Jun; 2(11):1229-1242. PubMed ID: 29853524
[TBL] [Abstract][Full Text] [Related]
17. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
[TBL] [Abstract][Full Text] [Related]
18. Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells.
Massimino M; Vigneri P; Stella S; Tirrò E; Pennisi MS; Parrinello LN; Vetro C; Manzella L; Stagno F; Di Raimondo F
J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884309
[TBL] [Abstract][Full Text] [Related]
19. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells.
Klein F; Feldhahn N; Herzog S; Sprangers M; Mooster JL; Jumaa H; Müschen M
Oncogene; 2006 Feb; 25(7):1118-24. PubMed ID: 16205638
[TBL] [Abstract][Full Text] [Related]
20. Targeting of heme oxygenase-1 attenuates the negative impact of Ikaros isoform 6 in adult BCR-ABL1-positive B-ALL.
Lin X; Zou X; Wang Z; Fang Q; Chen S; Huang J; Zhe N; Yu M; Zhang Y; Wang J
Oncotarget; 2016 Aug; 7(33):53679-53701. PubMed ID: 27447561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
